

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Humate-P safely and effectively. See full prescribing information for Humate-P.

Humate-P®

Antihemophilic Factor/von Willebrand Factor Complex (Human)
Lyophilized Powder for Reconstitution for Intravenous Use Only.
Initial U.S. Approval: 1986

INDICATIONS AND USAGE

Humate-P is an Antihemophilic Factor/von Willebrand Factor (VWF) Complex (Human) indicated for:

- Hemophilia A – Treatment and prevention of bleeding in adults (1.1).
- Von Willebrand disease (VWD) – in adults and pediatric patients in the (1) Treatment of spontaneous and trauma-induced bleeding episodes; it is not indicated for the prophylaxis of spontaneous bleeding episodes, and (2) Prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD as well as patients with mild to moderate VWD where the use of desmopressin is known or suspected to be inadequate (1.2). Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

DOSAGE AND ADMINISTRATION

For intravenous use only.

Hemophilia A

- One IU of factor VIII (FVIII) activity per kg body weight increases the circulating FVIII level by approximately 2.0 IU/dL. Individualize dosage based on the patient's weight, type and severity of hemorrhage, FVIII level, and presence of inhibitors (see *Table 1 for dosing recommendations*) (2.1).

VWD

- Treatment of bleeding episodes – Administer 40-80 IU VWF:Ristocetin Cofactor (RCo) per kg body weight every 8-12 hours (2.2).
- Prevention of excessive bleeding during and after surgery for all types of VWD (2.3).

Type of Surgery (see Table 3 for complete surgical dosing)	Calculation of Loading Dose Initial maintenance dose should be half the loading dose (see Table 4 for monitoring recommendations).
Major Surgery (2.3)	$\frac{\Delta * \text{VWF:RCo} \times \text{BW (kg)}}{\text{IVR}^\ddagger} = \text{IU VWF:RCo required}$
Minor / Oral Surgery [†] (2.3)	$\frac{\Delta * \text{VWF:RCo} \times \text{BW (kg)}}{\text{IVR}} = \text{IU VWF:RCo required}$
Emergency Surgery (2.3)	Administer a dose of 50-60 IU VWF:RCo/kg BW

BW = body weight.

* Δ = Target peak plasma VWF:RCo level – baseline plasma VWF:RCo level.

[†] IVR = *in vivo* recovery as measured in the patient. If the IVR is unknown, use 2.0 IU/dL per IU/kg.

[‡] Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement.

DOSAGE FORMS AND STRENGTHS

- Each vial of Humate-P lyophilized powder contains the labeled amount of VWF:RCo and FVIII activity expressed in IU*. The average ratio of VWF:RCo to FVIII is 2.4:1. Approximate potencies are shown below; check each carton/vial for the actual potency prior to reconstitution (3):

VWF:RCo/vial	FVIII/vial	Diluent
600 IU	250 IU	5 mL
1200 IU	500 IU	10 mL
2400 IU	1000 IU	15 mL

CONTRAINDICATIONS

- Anaphylactic or severe systemic reaction to antihemophilic factor or VWF preparations (4).

WARNINGS AND PRECAUTIONS

- VWD patients receiving Humate-P may be at risk of developing thromboembolic events (5.1).
- Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses (5.2).
- Monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery (5.3).
- Products made from human plasma may contain infectious agents (e.g., viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent) (5.4).

ADVERSE REACTIONS

- Most common adverse reactions observed by >5% of subjects after receiving Humate-P are allergic-anaphylactic reactions (e.g., urticaria, chest tightness, rash, pruritus, edema and, in patients undergoing surgery, postoperative wound and injection-site bleeding, and epistaxis) (6).

To report SUSPECTED ADVERSE REACTIONS, contact CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Pregnancy: No human or animal data. Use only if clearly needed (8.1).
- The hemostatic efficacy of Humate-P has been studied in 34 pediatric subjects with VWD (8.4). Based on the data from a subset of these subjects, age had no effect on the pharmacokinetics of VWF:RCo (12.3).

See 17 for PATIENT COUNSELING INFORMATION.

Revised: January 2010

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- Hemophilia A
- Von Willebrand Disease (VWD)

2 DOSAGE AND ADMINISTRATION

- Therapy for Hemophilia A
- Treatment of Bleeding Episodes in VWD
- Prevention of Excessive Bleeding During and After Surgery in VWD
- Reconstitution and Administration

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- Thromboembolic Events (VWD Patients)
- Monitoring for Intravascular Hemolysis
- Monitoring VWF:RCo and Factor VIII Levels
- Transmission of Infectious Agents

6 ADVERSE REACTIONS

- Clinical Studies Experience
- Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

- Pregnancy
- Labor and Delivery
- Nursing Mothers
- Pediatric Use
- Geriatric Use

11 DESCRIPTION

- Virus Reduction Capacity

12 CLINICAL PHARMACOLOGY

- Mechanism of Action
- Pharmacokinetics

14 CLINICAL STUDIES

- Treatment of Bleeding Episodes in VWD
- Prevention of Excessive Bleeding During and After Surgery in VWD
- Virus Transmission Studies

15 REFERENCES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

Humate-P®

Antihemophilic Factor/von Willebrand Factor Complex (Human)

1 INDICATIONS AND USAGE

1.1 Hemophilia A

Humate-P, Antihemophilic Factor/von Willebrand Factor Complex (Human), is indicated for treatment and prevention of bleeding in adults with hemophilia A (classical hemophilia).

1.2 Von Willebrand Disease (VWD)

Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for: (1) treatment of spontaneous and trauma-induced bleeding episodes, and

(2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD as well as patients with mild to moderate VWD where use of desmopressin (DDAVP) is known or suspected to be inadequate.

Controlled clinical trials to evaluate the safety and efficacy of prophylactic dosing with Humate-P to prevent spontaneous bleeding have not been conducted in VWD subjects (see *Clinical Studies [14]*).

2 DOSAGE AND ADMINISTRATION

2.1 Therapy for Hemophilia A

One IU of Factor VIII (FVIII) activity per kg body weight will increase the circulating FVIII level by approximately 2.0 International Units (IU)/dL. Dosage must be individualized based on the patient's weight, type and severity of hemorrhage, FVIII level, and presence of inhibitors. Judge the adequacy of treatment by clinical effects and, in all cases, adjust doses as needed based on clinical judgment and on frequent monitoring of the patient's FVIII level. Table 1 provides dosing recommendations for the treatment of hemophilia A in adults.

Table 1: Dosing Recommendations for the Treatment of Hemophilia A in Adults¹

Hemorrhagic Event	Dosage (IU FVIII:C/kg Body Weight)
Minor hemorrhage: <ul style="list-style-type: none"> • Early joint or muscle bleed • Severe epistaxis 	Loading dose 15 IU FVIII:C/kg to achieve a FVIII:C plasma level of approximately 30% of normal; one infusion may be sufficient. If needed, half of the loading dose may be given once or twice daily for 1-2 days.
Moderate hemorrhage: <ul style="list-style-type: none"> • Advanced joint or muscle bleed • Neck, tongue, or pharyngeal hematoma (without airway compromise) • Tooth extraction • Severe abdominal pain 	Loading dose 25 IU FVIII:C/kg to achieve a FVIII:C plasma level of approximately 50% of normal, followed by 15 IU FVIII:C/kg every 8-12 hours for the first 1-2 days to maintain the FVIII:C plasma level at 30% of normal. Continue the same dose once or twice daily for up to 7 days or until adequate wound healing is achieved.
Life-threatening hemorrhage: <ul style="list-style-type: none"> • Major surgery • Gastrointestinal bleeding • Neck, tongue, or pharyngeal hematoma (with potential for airway compromise) • Intracranial, intraabdominal, or intrathoracic bleeding • Fractures 	Initially 40-50 IU FVIII:C/kg, followed by 20-25 IU FVIII:C/kg every 8 hours to maintain the FVIII:C plasma level at 80-100% of normal for 7 days. Continue the same dose once or twice daily for another 7 days to maintain the FVIII:C level at 30-50% of normal.

IU = International Units.

2.2 Treatment of Bleeding Episodes in VWD

Administer 40 to 80 International Units (IU) VWF:RCo (corresponding to 17 to 33 International Units (IU) FVIII in Humate-P) per kg body weight every 8 to 12 hours. Adjust the dosage based on the extent and location of bleeding. Administer repeat doses as long as needed based on monitoring of appropriate clinical and laboratory measures (see *Warnings and Precautions [5.2 and 5.3]*). Expected levels of VWF:RCo are based on an expected *in vivo* recovery (IVR) of 2.0 International Units (IU)/dL rise per International Unit (IU)/kg VWF:RCo administered. The administration of 1 IU of FVIII per kg body weight can be expected to lead to a rise in circulating VWF:RCo of approximately 5 International Units (IU)/dL. Table 2 provides dosing recommendations for adult and pediatric patients (see also *Pediatric Use [8.4]*).²

Table 2: VWF:RCo Dosing Recommendations for the Treatment of Bleeding Episodes by VWD Type

VWD Type	Severity of Hemorrhage	Dosage (IU* VWF:RCo/kg Body Weight)
Type 1 VWD – Mild (baseline VWF:RCo activity typically >30%)	Minor (e.g., epistaxis, oral bleeding, menorrhagia)	Typically treatable with desmopressin.
	Minor (when desmopressin is known or suspected to be inadequate)	Loading dose 40-60 IU/kg. Then 40-50 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo >50%. Then 40-50 IU/kg daily for up to 7 days.
	Major† (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, traumatic hemorrhage)	
Type 1 VWD – Moderate or severe (baseline VWF:RCo typically <30%)	Minor (e.g., epistaxis, oral bleeding, menorrhagia)	40-50 IU/kg (1 or 2 doses).
	Major (e.g., severe or refractory epistaxis, GI bleeding, CNS trauma, hemarthrosis, traumatic hemorrhage)	Loading dose 50-75 IU/kg. Then 40-60 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo >50%. Then 40-60 IU/kg daily for up to 7 days.
Type 2 VWD (all variants) and Type 3 VWD	Minor (clinical indications above)	40-50 IU/kg (1 or 2 doses).
	Major (clinical indications above)	Loading dose 60-80 IU/kg. Then 40-60 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo >50%. Then 40-60 IU/kg daily for up to 7 days.

* IU = International Units.

† For major bleeds in all types of VWD where repeated dosing is required, monitor and maintain the patient's FVIII level according to the guidelines for hemophilia A therapy.

2.3 Prevention of Excessive Bleeding During and After Surgery in VWD

The following information provides guidelines for calculating loading and maintenance doses of Humate-P for patients undergoing surgery. However **in the case of emergency surgery**, administer a loading dose of 50 to 60 International Units (IU) VWF:RCo/kg body weight and, subsequently, closely monitor the patient's trough coagulation factor levels.

Measure incremental IVR and assess plasma VWF:RCo and FVIII:C levels in all patients prior to surgery when possible.

To determine IVR:

1. Measure the baseline plasma VWF:RCo level.
2. Infuse a calculated dose [International Units (IU)/kg] of VWF:RCo product intravenously at "time 0".
3. At "time+30 minutes", measure the plasma VWF:RCo level.

Use the following formula to calculate IVR:

$$IVR = \frac{\text{Plasma VWF:RCo}_{\text{time+30 min}} - \text{Plasma VWF:RCo}_{\text{baseline}}}{\text{International Units (IU)/dL}} \times \text{International Units (IU)/kg}$$

For example, assuming a baseline VWF:RCo of 30 International Units (IU)/dL at "time 0", a calculated dose of 60 International Units (IU)/kg, and a VWF:RCo of 120 International Units (IU)/dL at "time+30 minutes", the IVR would be 1.5 International Units (IU)/dL per International Units (IU)/kg of VWF:RCo administered.

Loading Dose

Table 3 provides guidelines for calculating the loading dose for adult and pediatric patients based on the target peak plasma VWF:RCo level, the baseline VWF:RCo level, body weight in kilograms, and IVR. When individual recovery values are not available, a standardized loading dose can be used based on an assumed VWF:RCo IVR of 2.0 International Units (IU)/dL per International Unit (IU)/kg of VWF:RCo administered.

Table 3: VWF:RCo and FVIII:C Loading Dose Calculations for the Prevention of Excessive Bleeding During and After Surgery for All Types of VWD

Type of Surgery	VWF:RCo Target Peak Plasma Level	FVIII:C Target Peak Plasma Level	Calculation of Loading Dose (to be administered 1 to 2 hours before surgery)
Major	100 IU/dL	80-100 IU/dL	$\Delta^{\pm} \text{VWF:RCo} \times \frac{\text{BW (kg)}}{\text{IVR}^{\dagger}} = \text{IU VWF:RCo required}$ <p>If the IVR is not available, assume an IVR of 2.0 IU/dL per IU/kg and calculate the loading dose as follows:</p> $(\text{100} - \text{baseline plasma VWF:RCo}) \times \text{BW (kg)} / 2.0$
Minor / oral [†]	50-60 IU/dL	40-50 IU/dL	$\Delta^{\pm} \text{VWF:RCo} \times \frac{\text{BW (kg)}}{\text{IVR}} = \text{IU VWF:RCo required}$
Emergency	100 IU/dL	80-100 IU/dL	Administer a dose of 50-60 IU VWF:RCo/kg body weight.

IU = International Units.

BW = body weight.

* Δ = Target peak plasma VWF:RCo level – baseline plasma VWF:RCo level.

† IVR = *in vivo* recovery as measured in the patient.

‡ Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement. Extraction of more than one impacted wisdom tooth is considered major surgery due to the expected difficulty of the surgery and the expected blood loss, particularly in subjects with type 2A or type 3 VWD. Extraction of more than two teeth is considered major surgery in all patients.

For example, the loading dose of Humate-P required assuming a target VWF:RCo level of 100 International Units (IU)/dL, a baseline VWF:RCo level of 20 International Units (IU)/dL, an IVR of 2.0 International Units (IU)/dL per International Units (IU)/kg, and a body weight of 70 kg would be 2,800 International Units (IU) VWF:RCo, calculated as follows:

$$\frac{(100 \text{ IU/dL} - 20 \text{ IU/dL}) \times 70 \text{ kg}}{2.0 \text{ (IU/dL)/(IU/kg)}} = 2,800 \text{ IU VWF:RCo required}$$

IU = International Units.

Attaining a target peak FVIII:C plasma level of 80 to 100 International Units (IU) FVIII:C/dL for major surgery and 40 to 50 International Units (IU) FVIII:C/dL for minor surgery or oral surgery might require additional dosing with Humate-P. Because the ratio of VWF:RCo to FVIII:C activity in Humate-P is 2.4:1, any additional dosing will increase VWF:RCo proportionally more than FVIII:C. Assuming an incremental IVR of 2.0 International Units (IU) VWF:RCo/dL per International Units (IU)/kg infused, additional dosing to increase FVIII:C in plasma will also increase plasma VWF:RCo by approximately 5 International Units (IU)/dL for each International Units (IU)/kg of FVIII administered.

Maintenance Doses

The initial maintenance dose of Humate-P for the prevention of excessive bleeding during and after surgery should be half of the loading dose, irrespective of additional dosing required to meet FVIII:C targets. Subsequent maintenance doses should be based on the patient's VWF:RCo and FVIII levels. Table 4 provides recommendations for target trough plasma levels (based on type of surgery and number of days following surgery) and minimum duration of treatment for subsequent maintenance doses. These recommendations apply to both adult and pediatric patients.

Table 4: VWF:RCo and FVIII:C Target Trough Plasma Level and Minimum Duration of Treatment Recommendations for Subsequent Maintenance Doses for the Prevention of Excessive Bleeding During and After Surgery

Type of Surgery	VWF:RCo Target Trough Plasma Level*		FVIII:C Target Trough Plasma Level*		Minimum Duration of Treatment
	Up to 3 days following surgery	After Day 3	Up to 3 days following surgery	After Day 3	
Major	>50 IU/dL	>30 IU/dL	>50 IU/dL	>30 IU/dL	72 hours
Minor	≥30 IU/dL	–	–	>30 IU/dL	48 hours
Oral [†]	≥30 IU/dL	–	–	>30 IU/dL	8-12 hours [‡]

IU = International Units.

* Trough levels for either coagulation factor should not exceed 100 IU/dL.

† Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement. Extraction of more than one impacted wisdom tooth is considered major surgery due to the expected difficulty of the surgery and the expected blood loss, particularly in subjects with type 2A or type 3 VWD. Extraction of more than two teeth is considered major surgery in all patients.

‡ Administer at least one maintenance dose following oral surgery based on individual pharmacokinetic values. Subsequent therapy with an antifibrinolytic agent is usually administered until adequate healing is achieved.

Based on individual pharmacokinetic-derived half-lives, the frequency of maintenance doses is generally every 8 or 12 hours; patients with shorter half-lives may require dosing every 6 hours. In the absence of pharmacokinetic data, it is recommended that Humate-P be administered initially every 8 hours with further adjustments determined by monitoring trough coagulation factor levels. When hemostatic levels are judged insufficient or trough levels are outside the recommended range, consider modifying the administration interval and/or the dose.

It is advisable to monitor trough VWF:RCo and FVIII:C levels at least once a day in order to adjust Humate-P dosing as needed to avoid excessive accumulation of coagulation factors. The duration of treatment generally depends on the type of surgery performed, but must be assessed for individual patients based on their hemostatic response (see *Clinical Studies [14.2]*).


2.4 Reconstitution and Administration

Humate-P is for intravenous (IV) use only.

Inspect visually for particulate matter and discoloration prior to administration.

Use either the Mix2Vial™ filter transfer set provided with Humate-P (see *How Supplied/Storage and Handling [16]*) or a commercially available double-ended needle and vented filter spike.

Plastic disposable syringes are recommended for use with Humate-P. Protein solutions of this type tend to adhere to the ground glass surface of all-glass syringes.

1. Ensure that the Humate-P and diluent are at room temperature. Using aseptic technique, follow these steps to reconstitute Humate-P.	
2. Place the product vial, diluent vial and Mix2Vial on a flat surface.	
3. Remove product and diluent vial flip caps and treat the stoppers with the alcohol swab provided, and allow to dry prior to opening the Mix2Vial package.	
4. Open the Mix2Vial package by peeling away the lid (Fig. 1). Leave the Mix2Vial in the clear package. Place the diluent vial on a flat surface and hold the vial tight. Grip the Mix2Vial together with the package and snap the blue end onto the diluent stopper (Fig. 2).	 Fig. 1  Fig. 2
5. Carefully remove the clear package from the Mix2Vial set. Make sure that you only pull up the package and not the Mix2Vial set (Fig. 3).	 Fig. 3
6. With the product vial placed firmly on a flat surface, invert the diluent vial with the set attached and snap the transparent adapter onto the product vial stopper (Fig. 4). The diluent will automatically transfer into the product vial.	 Fig. 4
7. With the diluent and product vial still attached, gently swirl the product vial to ensure the product is fully dissolved (Fig. 5). Do not shake vial.	 Fig. 5
8. With one hand grasp the product-side of the Mix2Vial set and with the other hand grasp the blue diluent-side of the Mix2Vial set and unscrew the set into two pieces (Fig. 6).	 Fig. 6

<p>9. Draw air into an empty, sterile syringe. While the product vial is upright, screw the syringe to the Mix2Vial set. Inject air into the product vial. While keeping the syringe plunger pressed, invert the system upside down and draw the concentrate into the syringe by pulling the plunger back slowly (Fig. 7).</p>	 <p>Fig. 7</p>
<p>10. Now that the concentrate has been transferred into the syringe, firmly grasp the barrel of the syringe (keeping the syringe plunger facing down) and unscrew the syringe from the Mix2Vial set (Fig. 8). Attach the syringe to a suitable intravenous (IV) administration set.</p>	 <p>Fig. 8</p>
<p>11. If the same patient is to receive more than one vial, you may pool the contents of multiple vials. Use a separate unused Mix2Vial for each product vial.</p>	

When the reconstitution procedure is followed precisely, it is not uncommon for a few small flakes or particles to remain. The Mix2Vial should remove those particles.

Do not refrigerate Humate-P after reconstitution. Administer within 3 hours after reconstitution.

Slowly infuse the solution (maximally 4 mL/minute) with a suitable IV administration set.

Discard the administration equipment and any unused Humate-P after use.

3 DOSAGE FORMS AND STRENGTHS

Humate-P is a sterile, lyophilized powder for intravenous administration. Each vial of Humate-P contains the labeled amount of VWF:RCo and FVIII activity expressed in International Units (IU). The average ratio of VWF:RCo to FVIII is 2.4:1.

Approximate potencies are shown below; check each carton/vial for the actual potency prior to reconstitution:

VWF:RCo/vial	FVIII/vial	Diluent
600 IU	250 IU	5 mL
1200 IU	500 IU	10 mL
2400 IU	1000 IU	15 mL

IU = International Units.

4 CONTRAINDICATIONS

Humate-P is contraindicated in individuals who have had an anaphylactic or severe systemic reaction to antihemophilic factor or von Willebrand factor preparations.

5 WARNINGS AND PRECAUTIONS

5.1 Thromboembolic Events (VWD Patients)

Thromboembolic events have been reported in VWD patients receiving Antihemophilic Factor/von Willebrand Factor Complex replacement therapy, especially in the setting of known risk factors for thrombosis.^{3,4} Early reports indicate a higher incidence may occur in females. Endogenous high levels of FVIII have also been associated with thrombosis, but no causal relationship has been established. Exercise caution and consider antithrombotic measures in all at-risk VWD patients who are receiving coagulation factor replacement therapy.

5.2 Monitoring for Intravascular Hemolysis

Humate-P contains blood group isoagglutinins (anti-A and anti-B). When doses are very large or need to be repeated frequently (for example, when inhibitors are present or when pre- and post-surgical care is involved), monitor patients of blood groups A, B, and AB for signs of intravascular hemolysis and decreasing hematocrit values and treat appropriately.

5.3 Monitoring VWF:RCo and FVIII Levels

Monitor the VWF:RCo and FVIII levels of VWD patients receiving Humate-P using standard coagulation tests, especially in cases of surgery. It is advisable to monitor trough VWF:RCo and FVIII:C levels at least once a day in order to adjust the dosage of Humate-P as needed to avoid excessive accumulation of coagulation factors (see *Dosage and Administration* [2.2, 2.3]).

5.4 Transmission of Infectious Agents

Humate-P is made from human plasma. Products made from human plasma may contain infectious agents (e.g., viruses and theoretically, the Creutzfeldt-Jakob disease [CJD] agent) that can cause disease (see *Description* [11] and *Patient Counseling Information* [17.1]). The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during manufacturing (see *Description* [11.1] for virus reduction measures).

Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. Thus the risk of transmission of infectious agents cannot be eliminated completely. **Report all infections thought by a physician possibly to have been transmitted by this product to CSL Behring Pharmacovigilance at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.**

Some viruses, such as Parvovirus B19 virus (B19V) or hepatitis A (HAV), are particularly difficult to remove or inactivate. B19V may most seriously affect pregnant women and immune-compromised individuals.

Although the overwhelming number of B19V and HAV cases are community acquired, reports of these infections have been associated with the use of some plasma-derived products. Therefore, physicians should be alert to the potential symptoms of B19V and HAV infections (see *Patient Counseling Information* [17.1]).

Symptoms of B19V may include low-grade fever, rash, arthralgias, and transient symmetric, nondestructive arthritis. Diagnosis is often established by measuring B19V-specific IgM and IgG antibodies. Symptoms of HAV include low-grade fever, anorexia, nausea, vomiting, fatigue, and jaundice. A diagnosis may be established by measuring specific IgM antibodies.

Physicians should strongly consider administration of hepatitis A and hepatitis B vaccines to individuals receiving plasma derivatives. Potential risks and benefits of vaccination should be weighed by the physician and discussed with the patient.

6 ADVERSE REACTIONS

The most serious adverse reaction observed in patients receiving Humate-P is anaphylaxis. Thromboembolic events have also been observed in patients receiving Humate-P for the treatment of VWD (see *Warnings and Precautions* [5.1]). Reports of thromboembolic events in VWD patients with other thrombotic risk factors receiving coagulation factor replacement therapy have been obtained from spontaneous reports, published literature, and a European clinical study. In some cases, inhibitors to coagulation factors may occur. However, no inhibitor formation was observed in any of the clinical studies.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions (including urticaria, chest tightness, rash, pruritus, and edema). For patients undergoing surgery, the most common adverse reactions are postoperative wound and injection-site bleeding, and epistaxis.

6.1 Clinical Studies Experience

Because clinical studies are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.

Treatment of Bleeding Episodes in VWD

Allergic symptoms, including allergic reaction, urticaria, chest tightness, rash, pruritus, and edema, were reported in 6 of 97 (6%) subjects in a Canadian retrospective study (see *Clinical Studies* [14.1]). Four of 97 (4%) subjects experienced seven adverse events that were considered to have a possible or probable relationship to Humate-P. These included chills, phlebitis, vasodilation, paresthesia, pruritus, rash, and urticaria. All were mild in intensity with the exception of a moderate case of pruritus.

In a prospective, open-label safety and efficacy study of Humate-P in VWD subjects with serious life- or limb-threatening bleeding or undergoing emergency surgery, seven of 71 (10%) subjects experienced nine adverse reactions. These were one occurrence each of mild vasodilation and mild pruritus; two occurrences of mild paresthesia; and one occurrence each of moderate peripheral edema and extremity pain and severe pseudothrombocytopenia (platelet clumping with a false low reading). Humate-P was discontinued in the subject who experienced the peripheral edema and extremity pain.

Prevention of Excessive Bleeding During and After Surgery in VWD

Among the 63 VWD subjects who received Humate-P for prevention of excessive bleeding during and after surgery, including one subject who underwent colonoscopy without the planned polypectomy, the most common adverse events were postoperative hemorrhage (35 events in 19 subjects with five subjects experiencing bleeding at up to three different sites), postoperative nausea (15 subjects), and postoperative pain (11 subjects). Table 5 presents the postoperative hemorrhagic adverse events.

Table 5: Hemorrhagic Adverse Events in 63 Surgical Subjects

Adverse Event	Surgical Procedure Category	Number of Subjects/ Events	Onset* (Number of Events)		Severity (Number of Events)		
			On	Post	Mild	Mod	Severe
Wound/injection site bleeding	Major	8/11	7	4	9	–	2
	Minor	2/2	2	–	1	1	–
	Oral	2/6	–	6	3	3	–
Epistaxis	Major	4/4	2	2	3	1	–
	Minor	1/1	1	–	1	–	–

Adverse Event	Surgical Procedure Category	Number of Subjects/ Events	Onset* (Number of Events)		Severity (Number of Events)		
Cerebral hemorrhage/ subdural hematoma	Major	1/2	2 [†]	–	–	2	–
Gastrointestinal bleeding	Major	1/3	3 [‡]	–	–	2	1
Menorrhagia	Major	1/1	1 [§]	–	–	1	–
Groin bleed	Oral	1/1	–	1	1	–	–
Ear bleed	Major	1/1	1	–	1	–	–
Hemoptysis	Major	1/1	1	–	1	–	–
Hematuria	Major	1/1	1	–	1	–	–
Shoulder bleed	Major	1/1	1	–	1	–	–

* On = on-therapy; onset while receiving Humate-P or within 1 day of completing Humate-P administration. Post = post-therapy; onset at least one day after completing Humate-P administration.

† Reported as serious adverse events following intracranial surgery.

‡ Two of these events were reported as serious adverse events following gastrojejun bypass.

§ Reported as a serious adverse event requiring hysterectomy following hysteroscopy and dilation and curettage.

Table 6 lists the non-hemorrhagic adverse events reported in at least two subjects, regardless of causality, and the adverse events that were possibly related to Humate-P. Pulmonary embolus considered possibly related to Humate-P occurred in one elderly subject who underwent bilateral knee replacement.

Table 6: Non-Hemorrhagic and Possibly Related Adverse Events in 63 Surgical Subjects

Body System	Adverse Event (AE)	Number of Subjects With an AE Possibly Related to Humate-P	Number of Subjects With an AE Regardless of Causality*
Body as a whole	Pain	–	11
	Fever	–	4
	Abdominal pain	–	3
	Infection	–	3
	Surgery	–	3
	Back pain	–	2
	Facial edema	–	2
Cardiovascular	Chest pain	–	3
	Pulmonary embolus [†]	1	1
	Thrombophlebitis [†]	1	1
Digestive	Nausea	1	15
	Constipation	–	7
	Vomiting	1	3
	Sore throat	–	2
Hemic and lymphatic system	Anemia / decreased hemoglobin	–	2
Metabolic/nutritional	Increased SGPT	1	1
Nervous	Dizziness	1	5
	Headache	1	4
	Increased sweating	–	3
	Insomnia	–	2
Skin and appendages	Pruritus	–	3
	Rash	1	1
Urogenital	Urinary retention	–	4
	Urinary tract infection	–	2

* Events occurring in two or more subjects.

† Events occurring in separate subjects.

Eight subjects experienced 10 postoperative serious adverse events: one with subdural hematoma and intracerebral bleeding following intracranial surgery related to an underlying cerebrovascular abnormality; one with two occurrences of gastrointestinal bleeding following gastrojejun bypass; and one each with sepsis, facial edema, infection, menorrhagia requiring hysterectomy following hysteroscopy and dilation and curettage, pyelonephritis, and pulmonary embolus.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of Humate-P. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Humate-P exposure.

Adverse reactions reported in patients receiving Humate-P for treatment of VWD or hemophilia A are allergic-anaphylactic reactions (including urticaria, chest tightness, rash, pruritus, edema, and shock), development of inhibitors to FVIII, and hemolysis. Additional adverse reactions reported for VWD are thromboembolic complications, chills and fever, and hypervolemia.

7 DRUG INTERACTIONS

None reported.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Humate-P. It is also not known whether Humate-P can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Humate-P should be given to a pregnant woman only if clearly needed.

8.2 Labor and Delivery

It is not known whether Humate-P can cause harm to the mother or the fetus when administered during labor and delivery. Humate-P should be given during labor and delivery only if clearly needed.

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Humate-P is administered to a nursing woman.

8.4 Pediatric Use

Hemophilia A

Adequate and well-controlled studies with long-term evaluation of joint damage have not been done in pediatric subjects. Joint damage may result from suboptimal treatment of hemarthroses.

VWD

The safety and effectiveness of Humate-P for the treatment of VWD was demonstrated in 26 pediatric subjects, including infants, children, and adolescents, but have not been evaluated in neonates. The safety of Humate-P for the prevention of excessive bleeding during and after surgery was demonstrated in eight pediatric subjects (ages 3 to 15) with VWD. Of the 34 pediatric subjects studied for either treatment of bleeding episodes in VWD or prevention of excessive bleeding during and after surgery, four were infants (1 month to under 2 years of age), 23 were children (2 through 12 years), and seven were adolescents (13 through 15 years).

As in adults, pediatric patients should be dosed based on body weight (kg) (see *Dosage and Administration* [2.2, 2.3]).

8.5 Geriatric Use

Clinical studies of Humate-P did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger subjects. As for all patients, dosing for geriatric patients should be appropriate to their overall situation.

11 DESCRIPTION

Humate-P, Antihemophilic Factor/von Willebrand Factor Complex (Human), is a purified, sterile, lyophilized concentrate of Factor VIII (FVIII) and von Willebrand Factor (VWF) (Human) to be administered by the intravenous route in the treatment of patients with classical hemophilia (hemophilia A) and VWD (see *Clinical Pharmacology* [12]).

Humate-P is purified from the cold insoluble fraction of pooled human plasma and contains purified and concentrated FVIII/VWF Complex (Human). Fibrinogen content is less than or equal to 0.2 mg/mL.

Each vial of Humate-P contains the labeled amount of vonWillebrand Factor:Ristocetin Cofactor (VWF:RCo) and FVIII activity expressed in International Units (IU) (see *Dosage Forms and Strengths* [3]). An International Unit (IU) is defined by the current international standard established by the World Health Organization. One International Unit (IU) of VWF:RCo or FVIII is approximately equal to the amount of VWF:RCo or FVIII in 1.0 mL of fresh-pooled human plasma. The average ratio of VWF:RCo to FVIII is 2.4:1.

When reconstituted with the volume of diluent (sterile water) provided, each mL of Humate-P contains 72 to 224 International Units (IU) VWF:RCo activity,* 40 to 80 International Units (IU) FVIII activity, 15 to 33 mg of glycine, 3.5 to 9.3 mg of sodium citrate, 2 to 5.3 mg of sodium chloride, 8 to 16 mg of Albumin (Human), 2 to 14 mg of other proteins, and 10 to 20 mg of total proteins. Humate-P contains no preservative.

Humate-P has been demonstrated in several studies to contain the high molecular weight multimers of VWF. This component is considered to be important for correcting the coagulation defect in patients with VWD.⁵ When administered to patients with VWD (types 1, 2, or 3), bleeding time decreased. This outcome was correlated with the presence of a multimeric composition of VWF similar to that found in normal plasma.⁶

Humate-P contains anti-A and anti-B blood group isoagglutinins (see *Warnings and Precautions* [5.2]).

The pooled human plasma used to produce Humate-P is collected from licensed facilities in the US. All source plasma used in the manufacture of Humate-P is tested by FDA-licensed Nucleic Acid Tests (NAT) for hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1) and

*This correlates to a VWF:RCo to FVIII activity average ratio of 2.4:1, which is used to calculate the nominal values of VWF:RCo activity and is the average VWF:RCo activity.

found to be nonreactive (negative). The source plasma is also tested by an investigational NAT for hepatitis B virus (HBV) and found to be nonreactive (negative). The purpose of the HBV test is to detect low levels of viral material; however, the significance of a nonreactive (negative) result has not been established.

11.1 Virus Reduction Capacity

The manufacturing procedure for Humate-P includes multiple processing steps that reduce the risk of virus transmission. The manufacturing process has been demonstrated to reduce the risk of virus transmission in an additive manner: 1) cryoprecipitation; 2) Al(OH)₃ adsorption, glycine precipitation, and NaCl precipitation, studied in combination; and 3) pasteurization in aqueous solution at 60°C for 10 hours. Total mean cumulative virus reductions ranged from 6.0 to $\geq 11.3 \log_{10}$ as shown in Table 7.

Table 7: Mean Virus Reduction Factors

Virus Studied	Cryoprecipitation [log ₁₀]	Al(OH) ₃ Adsorption / Glycine Precipitation / NaCl Precipitation [log ₁₀]	Pasteurization [log ₁₀]	Mean Cumulative Virus Reduction [log ₁₀]
Enveloped Viruses				
HIV-1	ND	3.6	≥ 6.4	≥ 10.0
BVDV	ND	2.4	≥ 8.9	≥ 11.3
PRV	1.6	3.7	4.6	9.9
WNV	ND	ND	≥ 7.8	NA
Non-Enveloped Viruses				
HAV	1.5	2.4	4.2	8.1
CPV	1.5	3.4	1.1	6.0
B19V	ND	ND	$\geq 3.9^*$	NA

ND, not determined; NA, not applicable; HIV-1, human immunodeficiency virus type 1, model for HIV types 1 and 2; BVDV, bovine viral diarrhea virus, model for HCV and WNV; PRV, pseudorabies virus, model for large enveloped DNA viruses (e.g., herpes virus); WNV, West Nile virus; HAV, hepatitis A virus; and CPV, canine parvovirus, model for Parvovirus B19 virus (B19V).

* The virus evaluation studies for B19V employed a novel experimental infectivity assay using a clone of the cell line U7 that contains erythropoietic progenitor cells; (residual) virus titer was determined using an immunofluorescence-based detection method.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The active components of Humate-P consist of two different noncovalently bound proteins (FVIII and VWF). FVIII is an essential cofactor in activation of factor X, leading ultimately to the formation of thrombin and, subsequently, fibrin. VWF promotes platelet aggregation and platelet adhesion on damaged vascular endothelium; activated platelets interact with clotting proteins to form a clot. VWF also serves as a stabilizing carrier protein for the procoagulant protein FVIII.^{7,8} The activity of VWF is measured as VWF:RCo.

12.3 Pharmacokinetics

Hemophilia A

After infusion of Humate-P, a rapid increase of plasma FVIII:C is followed by a rapid decrease in activity and, subsequently, a slower rate of decrease in activity. Studies with Humate-P in subjects with hemophilia A have demonstrated a mean half-life of 12.2 (range: 8.4 to 17.4) hours.

VWD

The pharmacokinetics of Humate-P were studied in 41 subjects in a US study and in 28 subjects in a European study (see *Clinical Studies [14.2]*). In both studies, subjects were evaluated in the nonbleeding state prior to a surgical procedure. Table 8 summarizes the pharmacokinetics of Humate-P based on these studies. Wide inter-subject variability was observed in pharmacokinetic values obtained from these studies.

Table 8: Pharmacokinetics of Humate-P in Two Studies of Subjects in the Non-Bleeding State Prior to Surgery

	US Study	European Study
Number of subjects	41	28
Type 1 VWD	16	10
Type 2A VWD	2	10
Type 2B VWD	4	--
Type 2M VWD	6	1
Type 3 VWD	13	7
Dosage of Humate-P	60 IU VWF:RCo/kg BW	80 IU VWF:RCo/kg BW
Median terminal half-life of VWF:RCo (range)	11 hours* (3.5-33.6)	10 hours [†] (2.8-28.3)
Median clearance (range)	3.1 mL/hr/kg (1-16.6)	4.8 mL/hr/kg (2.1-53)
Volume of distribution at steady state (range)	53 mL/kg (29-141)	59 mL/kg (32-290)
Median IVR for VWF:RCo activity (range)	2.4 IU/dL per IU/kg (1.1-4.2)	1.9 IU/dL per IU/kg (0.6-4.5)

IU = International Units.
BW = body weight.

* Excluding 5 subjects with a half-life exceeding the blood sampling time of 24 or 48 hours.

† Excluding 1 subject with a half-life exceeding the blood sampling time of 48 hours.

The multimeric patterns of Humate-P in the US study, were measured in 13 subjects with type 3 VWD; 11 had absent or barely detectable multimers at baseline. Of those 11 subjects, all had some high molecular weight multimers present 24 hours after infusion of Humate-P. In the European study, infusion of Humate-P corrected the defect of the multimer pattern in subjects with types 2A and 3 VWD. High molecular weight multimers were detectable until at least 8 hours after infusion.

Based on the small sample size evaluation, it appears that age, sex, and type of VWD have no impact on the pharmacokinetics of VWF:RCo.

14 CLINICAL STUDIES

Controlled clinical studies to evaluate the safety and efficacy of prophylactic dosing with Humate-P to prevent spontaneous bleeding have not been conducted in VWD subjects. Adequate data are not presently available on which to evaluate or to base dosing recommendations in this setting.

14.1 Treatment of Bleeding Episodes in VWD

Clinical efficacy of Humate-P in the control of bleeding in subjects with VWD was determined by a retrospective review of clinical safety and efficacy data obtained from 97 Canadian VWD subjects who received product under an Emergency Drug Release Program. The dosage schedule and duration of therapy were determined by the medical practitioner.

There were 514 requests for product use for surgery, bleeding, or prophylaxis in the 97 subjects. Of these, Humate-P was not used in 151 cases, and follow-up safety and/or efficacy information was available for 303 (83%) of the remaining 363 requests. In many cases, Humate-P from a single request was used for several treatment courses in one subject. Therefore, there are more reported treatment courses than requests.

Humate-P was administered to 97 subjects in 530 treatment courses: 73 for surgery, 344 for treatment of bleeding, and 20 for prophylaxis of bleeding. The majority of the 93 "other" uses involved dental procedures, diagnostic procedures, prophylaxis prior to a procedure, or test doses.

Table 9 summarizes the dosing information (all subjects) for bleeding episodes.

Table 9: Dosing Information for Bleeding Episodes in VWD

		Type/Location of Bleeding Episode				
		Digestive System	Nose+Mouth +Pharynx	Integument System	Female Genital System	Musculo-skeletal
No. of Subjects		14	29	11	4	22
Loading Dose	Mean Dose (SD)*	62.1 (31.1)	66.9 (24.3)	73.4 (37.7)	88.5 (28.3)	50.2 (24.9)
	No. of Infusions [†]	37	127	22	7	107
Maintenance Dose	Mean Dose (SD)*	61.5 (38.0)	67.5 (22.4)	56.5 (63.3)	74.5 (17.7)	63.8 (28.8)
	No. of Infusions [†]	250	55	4	15	121
No. of Treatment Days per Bleeding Episode	Mean (SD)	4.6 (3.6)	1.4 (1.2)	1.1 (0.4)	2.8 (2.9)	2.0 (1.9)
	No. of Events	49	130	22	9	108
No. of Infusions by Treatment Day						
No. of Subjects		14	29	11	4	22
Day 1 [‡]	Mean (SD)	1.2 (0.4)	1.1 (0.2)	1.0 (0.2)	1.0 (0.0)	1.0 (0.1)
	No. of Events	49	130	22	9	108
No. of Subjects		13	9	3	1	15
Day 2	Mean (SD)	1.2 (0.6)	1.3 (0.5)	1.0 (0.0)	1.0 (-)	1.2 (0.5)
	No. of Events	41	12	3	1	26
No. of Subjects		12	6	-	2	10
Day 3	Mean (SD)	1.5 (0.8)	1.4 (0.7)	-	1.0 (0.0)	1.2 (0.4)
	No. of Events	25	9	-	3	18

SD, standard deviation.

* IU VWF:RCo/kg.

† Number of infusions where the dose per kg body weight was available.

‡ Day 1, first treatment day.

14.2 Prevention of Excessive Bleeding During and After Surgery in VWD

Two prospective, open-label, non-controlled, multicenter clinical studies, one in the US and one in Europe, investigated the safety and hemostatic efficacy of Humate-P in subjects with VWD undergoing surgery.

- US clinical study** – The primary objective of this study was to demonstrate the safety and hemostatic efficacy of Humate-P in preventing excessive bleeding in adult and pediatric subjects with VWD undergoing surgery. The 35 subjects (21 female and 14 male) ranged in age from 3 to 75 years (mean 32.9); seven were age 15 or younger and two were age 65 or older. Twelve subjects had type 1 VWD, two had type 2A, three had type 2B, five had type 2M, and 13 had type 3. Twenty-eight of the surgical procedures were classified as major (e.g., orthopedic joint replacement, intracranial surgery, multiple tooth extractions, laparoscopic cholecystectomy), four as minor (e.g., placement of intravenous access device), and three subjects had oral surgery.* Seven of the 13 subjects with type 3 VWD had major surgery.

The first 15 subjects received a loading dose of Humate-P corresponding to 1.5 times the “full dose” (defined as the dose predicted to achieve a peak VWF:RCo level of 100 International Units (IU)/dL as determined by each subject’s calculated IVR and baseline VWF:RCo level); the loading dose did not vary with the type of surgery performed (i.e., major, minor, or oral). The remaining 20 subjects were dosed based on individual pharmacokinetic assessments and target peak VWF:RCo levels of 80 to 100 International Units (IU)/dL for major surgery and 50 to 60 International Units (IU)/dL for minor or oral surgery, respectively. All 35 subjects received initial maintenance doses corresponding to 0.5 times the full dose at intervals of 6, 8, or 12 hours after surgery as determined by their individual half-lives for VWF:RCo; subsequent maintenance doses were adjusted based on regular measurements of trough VWF:RCo and FVIII:C levels. The median duration of treatment was 1 day (range: 1 to 2 days) for oral surgery, 5 days (range: 3 to 7 days) for minor surgery, and 5.5 days (range: 2 to 26 days) for major surgery.

- European clinical study** –The primary objective of this study was to assess the ability of Humate-P to effectively correct the coagulation defect in subjects with VWD undergoing elective surgery, as demonstrated by an increase in VWF:RCo and FVIII, a shortening of the prolonged bleeding time, and the prevention and/or cessation of excessive bleeding. This study did not have a pre-stated hypothesis to evaluate hemostatic efficacy. The 27 subjects (18 females and nine males) ranged in age from 5 to 81 years (median age: 46 years); one was age 5, and five were older than 65. Ten subjects had type 1 VWD, nine had type 2A, one had type 2M, and seven had type 3. Sixteen of the surgical procedures were classified as major (orthopedic joint replacement, hysterectomy, multiple tooth extractions, laparoscopic adnexectomy, laparoscopic cholecystectomy, and basal cell carcinoma excision). Six of the seven subjects with type 3 VWD had major surgery.

Dosing was individualized based on a pharmacokinetic assessment performed before surgery. The median duration of treatment was 3.5 days (range: 1 to 17 days) for minor surgery and 9 days (range: 1 to 17 days) for major surgery.

In both studies, assessments of the hemostatic efficacy of Humate-P in preventing excessive bleeding were performed at the end of surgery, 24 hours after the last infusion of Humate-P, and at the end of the study (14 days following surgery).

Table 10 summarizes the end-of-surgery hemostatic efficacy assessments in subjects participating in either the US or European study.

Table 10: Investigator’s End-of-Surgery Hemostatic Efficacy Assessments for the US and European Surgical Studies

	Number of Subjects	End-of-Surgery Hemostatic Efficacy Assessments	
		Effective (Excellent / Good)*	95% Confidence Interval (CI) for Effective Proportion*
US study	35	32 (91.4%)	78.5-97.6%
European study	26 [†]	25 (96%)	82-99.8%

- * Excellent: Hemostasis clinically not significantly different from normal.
- Good: Mildly abnormal hemostasis in terms of quantity and/or quality (e.g., slight oozing).
- * 95% CIs according to Blyth-Still-Casella.
- [†] One subject with missing information.

Table 11 summarizes the overall hemostatic efficacy assessments in subjects participating in either the US or European study. Humate-P was effective in preventing excessive bleeding during and after surgery.

* Oral surgery is defined as extraction of fewer than three teeth, if the teeth are non-molars and have no bony involvement. Extraction of more than one impacted wisdom tooth is considered major surgery due to the expected difficulty of the surgery and the expected blood loss, particularly in subjects with type 2A or type 3 VWD. Extraction of more than two teeth is considered major surgery in all patients.

Table 11: Investigator’s Overall Hemostatic Efficacy Assessments for the US and European Surgical Studies

	Number of Subjects	Overall Hemostatic Assessments	
		Effective (Excellent / Good) [#]	95% CI for Effective Proportion*
US study [†]	35	35 (100%)	91.3-100%
European study [‡]	27	26 (96.3%)	82.5-99.8%

- [#] Excellent: Hemostasis clinically not significantly different from normal.
- Good: Mildly abnormal hemostasis in terms of quantity and/or quality (e.g., slight oozing).
- * 95% CIs according to Blyth-Still-Casella.
- [†] Overall hemostatic efficacy was assessed 24 hours after the last Humate-P infusion or 14 days after surgery, whichever came earlier.
- [‡] Overall hemostatic efficacy was not prospectively defined for the European study; the efficacy result displayed is the least efficacious ranking assigned by an investigator between surgery and Day 14.

In the US study, all efficacy assessments were reviewed by an independent Data Safety Monitoring Board (DSMB). The DSMB agreed with the investigators’ assessments of the overall hemostatic efficacy for all but two subjects (neither of whom had type 3 VWD). Based on this, the DSMB judged hemostatic efficacy as “effective” in 33 (94.3%) (95% CI: 81.1% to 99.0%) of the 35 subjects.

In the US study, the median actual estimated blood loss did not exceed the median expected blood loss, regardless of the type of surgery. Table 12 shows the median expected and actual estimated blood loss during surgery in the US study.

Table 12: Expected and Actual Estimated Blood Loss During Surgery in the US Study

Estimated Blood Loss	Oral Surgery (n=3)	Minor Surgery (n=4)	Major Surgery (n=28)	Total (n=35)
Expected – Median (range) mL	10 (5-50)	8 (0-15)	50 (0-300)*	20 (0-300)*
Actual – Median (range) mL	3 (0-15)	3 (0-10)	26 (0-300) [†]	18 (0-300) [†]

- * One subject with missing information
- [†] Five subjects with missing information

In the US study, four subjects received transfusions, three due to adverse events and one due to pre-existing anemia. In the European study, one subject received transfusions to treat pre-existing anemia.

14.3 Virus Transmission Studies

Clinical evidence of the absence of virus transmission in Humate-P was obtained in additional studies.

In one study, none of the evaluable subjects (31 of 67) who received Humate-P developed HBV infection or showed clinical signs of non-A, non-B (NANB) hepatitis infection.

In another study, 32 lots of Humate-P were administered to 26 subjects with hemophilia or VWD who had not previously received any blood products. No subject developed any signs of an infectious disease, and the 10 subjects not previously vaccinated remained seronegative for markers of infection with HBV, HAV, cytomegalovirus (CMV), Epstein-Barr virus, and HIV.

In a retrospective study, 155 subjects evaluated remained negative for the presence of HIV-1 antibodies for time periods ranging from 4 months to 9 years from the initial administration of Humate-P. All 67 of the subjects tested for HIV-2 antibodies remained seronegative.

15 REFERENCES

- Levine PH, Brettler DB. Clinical aspects and therapy for hemophilia A. In: Hoffman R, Benz JB, Shattil SJ, Furie B, Cohen HJ, eds. *Hematology: Basic Principles and Practice*. New York: Churchill Livingstone Inc.; 1991:1296-1297.
- Scott JP, Montgomery RT. Therapy of von Willebrand disease. *Semin Thromb Hemost*. 1993;19:37-47.
- Mannucci, PM. Venous Thromboembolism in Von Willebrand Disease. *Thromb Haemostas*. 2002;88:378-379.
- Markis M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. *Thromb Haemostas*. 2002;88:387-388.
- Berntorp E, Nilsson IM. Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates. *Eur J Haematol*. 1988;40:205-214.
- Berntorp E. Plasma product treatment in various types of von Willebrand’s disease. *Haemostasis*. 1994;24:289-297.
- Hoyer LW. The factor VIII complex: structure and function. *Blood*. 1981;58:1-13.
- Meyer D, Girma J-P. von Willebrand factor: structure and function. *Thromb Haemostas*. 1993;70:99-104.

16 HOW SUPPLIED/STORAGE AND HANDLING

Humate-P is supplied in a single-dose vial containing the labeled amount of VWF:RCo and FVIII activity expressed in International Units (IU). Each package contains a vial of Humate-P, a vial of diluent containing sterile water (meets USP chemistry requirements Sterile Water for Injection, except for pH), a Mix2Vial filter transfer set, and two alcohol swabs.

The components used in the packaging for Humate-P contain no latex.

Approximate potencies are shown below; check each carton/vial for the actual potency prior to reconstitution:

NDC Number	VWF:RCo/vial	FVIII/vial	Diluent
63833-615-02	600 IU	250 IU	5 mL
63833-616-02	1200 IU	500 IU	10 mL
63833-617-02	2400 IU	1000 IU	15 mL

IU = International Units.

When stored at temperatures up to 25°C (77°F), Humate-P is stable for 24 months up to the expiration date printed on its label. Do not freeze.

This product does not contain a preservative and should be used within 3 hours after reconstitution.

17 PATIENT COUNSELING INFORMATION

Inform patients that Humate-P is made from human plasma (part of the blood) and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain that the risk that Humate-P may transmit an infectious agent has been reduced by screening plasma donors, by testing the donated plasma for certain virus infections, and by inactivating and/or removing certain viruses during manufacturing (see

Warnings and Precautions [5.4]).

Inform patients that some viruses, such as B19V and HAV, may be particularly difficult to remove or inactivate. Advise patients, especially pregnant women and immune-compromised individuals, to report low-grade fever, rash, joint pain, anorexia, nausea, vomiting, fatigue, and jaundice (see *Warnings and Precautions [5.4]).*

Manufactured by:

CSL Behring GmbH
35041 Marburg, Germany
US License No. 1765

Distributed by:

CSL Behring LLC
Kankakee, IL 60901 USA

Mix2Vial is a trademark of West Pharmaceuticals Services, Inc.